2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance rangeAnnounced transactions of $13 billion since 2020 expected to add approximately $1.2 billion to Portfolio Receipts in 2025 NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2023 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma's founder and Chief Exec ...

Royalty Pharma PLC (NASDAQ:RPRX) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants George Grofik - SVP & Head, IR & Communications Pablo Legorreta - Founder, Chairman & CEO Christopher Hite - Vice Chairman & EVP Terrance Coyne - EVP & CFO Marshall Urist - EVP & Head, Research & Investments Conference Call Participants Christopher Schott - JPMorgan Chase & Co. Stephen Scala - TD Cowen Andrew Baum - Citigroup Michael DiFiore - Evercore ISI Chris Shibutani - Goldman Sachs Group ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (State or other jurisdiction of incorporation or organization) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ ...

Royalty Pharma plc (NASDAQ:RPRX) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Pablo Legorreta - Chief Executive Officer Marshall Urist - Executive Vice President, Head of Research and Investment Terrance Coyne - Executive Vice President, Chief Financial Officer Chris Hite - Executive Vice President, Vice Chairman George Grofik - Head of Investor Relations and Communications Conference Call Participants Chris Shibutani - Goldman Sachs Hardik Parekh - JP Morgan Geoff Meacha ...

ROYALTY PHARMA Q2 2023 Financial Results 2 Also, the discussions during this conference call will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). Additional information regarding non-GAAP financial measures can be found on slide 24 and in the Company's earnings release furnished with its Current Report on Form 8-K dated August 8, 2023, which are available on the Company's website. Any non-GAAP financial measures presented a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 ...

Q1 2023 Financial Results Forward Looking Statements & Non-GAAP Financial Information 3 | --- | --- | --- | |-------------------|----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------| | Portfolio Update | Marshall Urist | EVP, Head of Research & Investments | | Financial Results | Terrance Coyne | EVP, Chief Financial Officer | | Conclusion | Pablo Legorreta | Founder & Chief Executiv ...

Royalty Pharma plc (NASDAQ:RPRX) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head-Investor Relations and Communications Pablo Legorreta – Founder and Chief Executive Officer Marshall Urist – Executive Vice President, Head-Research and Investments Terry Coyne – Executive Vice President and Chief Financial Officer Chris Hite – Executive Vice President and Vice Chairman Conference Call Participants Chris Shibutani – Goldman Sachs Chris Sch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 ...

Royalty Pharma plc (NASDAQ:RPRX) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants George Grofik - Senior Vice President, Head of Investor Relations & Communications Pablo Legorreta - Founder & Chief Executive Officer Christopher Hite - Executive Vice President & Vice Chairman Marshall Urist - Executive Vice President & Head of Research and Investments Terry Coyne - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sach ...